BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Marginal Zone Lymphoma
Follicular Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab

Sponsor

BeiGene